InvestorsHub Logo
Followers 22
Posts 3618
Boards Moderated 0
Alias Born 07/20/2006

Re: cpaok1 post# 18272

Thursday, 03/08/2018 7:47:09 PM

Thursday, March 08, 2018 7:47:09 PM

Post# of 20689
Does anything in the most recent conference call support current stock action?

All speculation, but ----

Rumor has it they are working with an investment banker to either sell their Humira biosimilar and/or seek additional partnerships for their novel drugs. IMO - this could happen at any time.

Glatopa 40mg is another wild card. We'll know more with Novartis' 1st Q report in late April (?).

CW kept repeating that this year is going to be positive. [Fourth Quarter 2017 Earnings Call]

Also, their R & D day in Aug/Sept might be quite informative.

Plus -

Momenta Pharmaceuticals Inc (NASDAQ:MNTA) had a decrease of 8.97% in short interest. MNTA’s SI was 5.52 million shares in March as released by FINRA. Its down 8.97% from 6.06 million shares previously. With 959,200 avg volume, 6 days are for Momenta Pharmaceuticals Inc (NASDAQ:MNTA)’s short sellers to cover MNTA’s short positions. The SI to Momenta Pharmaceuticals Inc’s float is 7.59%. The stock decreased 0.28% or $0.05 during the last trading session, reaching $17.55. About 606,756 shares traded. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 54.42% since March 8, 2017 and is uptrending. It has outperformed by 37.72% the S&P500.

https://www.bibeypost.com/0-30-eps-expected-for-stellus-capital-investment-scm-shorts-at-momenta-pharmaceuticals-mnta-lowered-by-8-97/